ArticleJuntendo medical journal2025
Co-occurrence of Down Syndrome and Multiple Sclerosis.
Article in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Object: Down syndrome (DS) is often associated with autoimmune diseases; however, its association with multiple sclerosis (MS) has rarely been reported. In a previous report, the coincidence of DS and MS showed a negative association. Here, we searched for the coincidence of DS and MS, and attempted to resolve this negative association, focusing on the gene dosage effect, by utilizing available reports. Case presentation: A 44-year-old woman with DS experienced a progressively worsening gait at onset. Auto-immuno-antibodies including aquaporin-4 antibody were negative. On the basis of brain magnetic resonance image (MRI) findings, the patient was diagnosed with possible MS. After three years, the patient demonstrated additional signs and regression symptoms. Re-examined brain MRI showed multiple new focal lesions. Based on the McDonald criteria, the patient was diagnosed with laboratory-supported defined MS. Discussion: To date, we have found only one case report in the literature describing the development of MS in a 49-year-old man with DS. The protective effect of DS against the development of MS might be mediated by a gain of function due to a gene dosage effect, and the effect of candidate antigens could be interferon alpha and beta receptors, S100B, and amyloid precursor protein (APP). Conclusions: In patients with DS, S100B and APP overexpression could protect against MS, but both correlate with the progression of Alzheimer's neuropathological changes. S100B and APP can be seemed to be multiple pathogenesis and co-occurrence of MS with DS and Alzheimer's dementia may advance more severely than MS without DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.